The role of neuropeptide FF (NPFF) in the expression of sensitization to hyperlocomotor effect of morphine and ethanol

Neuropeptides

Volumn 41, Issue 1, 2007, Pages 51-58

  Kotlinska, Jolanta ^a   Pachuta, Agnieszka ^a   Dylag, Tomasz ^b   Silberring, Jerzy ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Ethanol; Locomotor activity; Morphine; Neuropeptides; NPFF; Sensitization

Indexed keywords

ALCOHOL; MORPHINE; NEUROPEPTIDE FF;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG POTENCY; HYPERACTIVITY; LOCOMOTION; MOTOR COORDINATION; MOUSE; NEUROPHARMACOLOGY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; ROTAROD TEST; SENSITIZATION;

ANIMALS; DRUG INTERACTIONS; ETHANOL; MALE; MICE; MORPHINE; MOTOR ACTIVITY; OLIGOPEPTIDES; ROTAROD PERFORMANCE TEST;

ANIMALIA;

EID: 33846081122     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.npep.2006.09.048     Document Type: Article

References (62)

1. Allard M., Geoffre S., Legendre P., Vincent J.D., and Simonnet G. Characterization of rat spinal cord receptors to FLFQPQRF amide, a mammalian morphine modulating peptide: a binding study. Brain Res. 500 (1989) 169-176
2. Allard M., Zajac J.M., and Simonnet G. Autoradiographic distribution of receptors to FLFQPQRF amide, a morphine-modulating peptide, in rat central nervous system. Neuroscience 49 (1992) 101-116
3. Attila M., Kurkijarvi U., Kivipelto L., Panula P., and Ahtee L. The antiopioid peptide, neuropeptide FF, enhances the effects of acute morphine on the cerebral monoamines in rats. Pharmacol. Res. 32 (1995) 293-298
4. Babbini M., and Davis W.M. Time-dose relationships for locomotor activity effects of morphine after acute or repeated treatment. Br. J. Pharmacol. 46 (1972) 213-224
5. Ballet S., Mauborgne A., Gouarderes C., Bourgoin A.S., Hamon M., Zajac J.-M., and Cesselin F. The neuropeptide FF analogue, 1DME, enhances in vivo met-enkephalin release from the rat spinal cord. Neuropharmacology 38 (1999) 1317-1324
6. Berridge K.C., and Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Rev. 28 (1998) 309-369
7. Bonini J.A., Jones K.A., Adham N., Forray C., Artymyshyn R., Durkin M.M., Smith K.E., Tamm J.A., Boteju L.W., Lakhlani P.P., Raddatz R., Yao W.J., Ogozalek K.L., Boyle N., Kouranova E.V., Quan Y., Vaysse P.J., Wetzel J.M., Branchek T.A., Gerald C., and Borowsky B. Identification and characterization of two G protein-coupled receptors for neuropeptide FF. J. Biol. Chem. 275 (2000) 39324-39331
8. Cador M., Marco N., Stinus L., and Simonnet G. Interaction between neuropeptide FF and opioids in the ventral tegmental area in the behavioral response to novelty. Neuroscience 110 (2002) 309-318
9. Cesselin F. Opioid and anti-opioid pepides. Fundam. Clin. Pharmacol. 9 (1995) 409-443
10. Chen J.C., Li J.Y., Liang K.W., and Huang Y.K. Neuropeptide FF potentiates the behavioral sensitization to amphetamine and alters the levels of neurotransmitters in the medial prefrontal cortex. Brain Res. 816 (1999) 220-224
11. Chen J.C., Lee W.-H., Chen P.-C., Tseng C.-P., and Huang E.Y.-K. Rat NPFF1 receptor-mediated signaling: functional comparison of neuropeptide FF (NPFF), FMRFamide and PFR(Tic)amide. Peptides 27 (2006) 1005-1014
12. Del Rosario C.N., Pacchioni A.M., and Cancela L.M. Influence of acute or repeated restraint stress on morphine-induced locomotion: involvement of dopamine, opioid and glutamate receptors. Behav. Brain Res. 134 (2002) 229-238
13. Devillers J.P., Boisserie F., Laulin J.P., Larcher A., and Simonnet G. Simultaneous activation of spinal antiopioid system (neuropeptide FF) and pain facilitatory circuitry by stimulation of opioid receptors in rats. Brain Res. 700 (1995) 173-181
14. Gardell L.R., Wang R., Burgess S.E., Ossipov M.H., Vanderah T.W., Malan Jr. T.P., Lai J., and Porreca F. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J. Neurosci. 22 (2002) 6747-6755
15. Gouarderes C., Sutek M., Zajac J.-M., and Jhamandas K. Antinociceptive effects of intrathecall administerd F8Famide and FMR-Famide in the rat. Eur. J. Pharmacol. 237 (1993) 73-81
16. Herz A. Endogenous opioid system and alcohol addiction. Psychopharmacology 129 (1997) 99-111
17. Joyce E.M., and Iversen S.D. The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci. Lett. 14 (1979) 207-212
18. Kalivas P.W., and Duffy P. Sensitization to repeated morphine injection in the rat: possible involvement of A10 dopamine neurons. J. Pharmacol. Exp. Ther. 241 (1987) 204-212
19. Kalivas P.W., and Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res. Rev. 16 (1991) 223-244
20. Kavaliers M. Inhibitory influences of mammalian FMRFamide (Phe-Met-Arg-Phe-amide)-related peptides on nociception and morphine- and stress-induced analgesia in mice. Neurosci. Lett. 115 (1990) 307-312
21. Kavaliers M., and Yang H.-Y. IgG from antiserum against endogenous mammalian FMRF-NH2-related peptides augments morphine- and stress-induced analgesia in mice. Peptides 10 (1989) 741-745
22. Koetzner L., Hua X.Y., Lai J., Porreca F., and Yaksh T. Nonopioid actions of intrathecal dynorphin evoke spinal excitatory amino acid and prostaglandin E2 release mediated by cyclooxygenase-1 and -2. J. Neurosci. 24 (2004) 1451-1458
23. Kokkinnidis L., and Zacharo R.M. Enhanced self-stimulation responding from the substantia nigra after chronic amphetamine treatment: a role for conditioning factors. Pharmacol. Biochem. Behav. 12 (1980) 543-547
24. Kotani M., Mollereau C., Detheux M., Le Poul E., Brezillon S., Vakili J., Mazarguil H., Vassart G., Zajac J.-M., and Parmentier M. Functional characterization of a human receptor for neuropeptide FF and related peptides. Br. J. Pharmacol. 133 (2001) 138-144
25. Kotlinska J., Bochenski M., and Danysz W. N-methyl-d-aspartate and group I metabotropic glutamate receptors are involved in the expression of ethanol-induced sensitization in mice. Behav Pharmacol. 17 (2006) 1-8
26. Kuribara H. Modification of morphine sensitization by opioid and dopamine receptor antagonists: evaluation by studying ambulation in mice. Eur. J. Pharmacol. 275 (1995) 251-258
27. Kuribara H. Induction of sensitization to hyperactivity caused by morphine in mice: effects of post-drug environments. Pharmacol. Biochem. Behav. 57 (1997) 341-346
28. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J. Pharmacol. Meth. 16 (1986) 355-357
29. Lessov C.N., and Phillips T.J. Duration of sensitization to the locomotor stimulant effects of ethanol in mice. Psychopharmacology 135 (1998) 374-382
30. Liu Q., Guan X.M., Martin W.J., McDonald T.P., Clements M.K., Jiang Q., Zeng Z., Jacobson M., Williams D.L.Jr., Yu H., Bomford D., Figueroa D., Mallee J., Wang R., Evans J., Gould R., and Austin C.P. Identification and characterization of novel mammalian neuropeptide FF-like peptides that attenuate morphine-induced antinociception. J. Biol. Chem. 276 (2001) 36961-36969
31. Majanem E.A., and Yang H.Y. FMRF-NH2-like peptide is deficient in the pituitary gland of the Brattleboro rat. Peptides 11 (1990) 345-349
32. Majane E.A., Zhu J., Aarnisalo A.A., Panula P., and Yang H.Y. Origin of neurohypophyseal neuropeptide-FF (FLFQPQRF-NH2). Endocrinoogy 133 (1993) 1578-1584
33. Malin D.H., Lake J.R., Fowler D.E., Hammond M.V., Brown S.L., Leyva J.E., Prasco P.E., and Doughert T.M. FMRF-NH2-like mammalian peptide precipitates opiate-withdrawal syndrome in the rat. Peptides 11 (1990) 277-280
34. Marchand S., Betourne A., Marty V., Daumas S., Halley H., Lassalle J.M., Zajac J.M., and Frances B. A neuropeptide FF agonist blocks the acquisition of conditioned place preference to morphine in C57Bl/6J mice. Peptides 27 (2006) 964-972
35. Marco N., Stinus L., Allard M., Le Moal M., and Simonnet G. Neuropeptide FLFQRFamide receptors within the ventral mesencephalon and dopaminergic terminal areas: localization and functional antiopioid involvement. Neuroscience 64 (1995) 1035-1044
36. Mauborgne A., Bourgoin S., Polienor H., Roumy M., Simonnet G., Zajac J.M., and Cesselin F. The neuropeptide FF analogue, 1DMe, acts as a functional opioid autoreceptor antagonist in the rat spinal cord. Eur. J. Pharmacol. 430 (2001) 273-276
37. Nestler E.J., and Aghajanian G.K. Molecular and cellular basis of addiction. Science 278 (1997) 58-63
38. Ng G.Y., O'Dowd B.F., and George S.R. Genotypic differences in mesolimbic enkephalin gene expression in DBA/2J and C57BL/6J inbred mice. Eur. J. Pharmacol. 311 (1996) 45-52
39. Panula P., Aarnisalo A.A., and Wasowicz K. Neuropeptide FF, a mammalian neuropeptide with multiple functions. Prog. Neurobiol. 48 (1996) 461-487
40. Panula P., Kalso E., Nieminen M., Kontinen V.K., Brandt A., and Pertovaara A. Neuropeptide FF and modulation of pain. Brain Res. 848 (1999) 191-196
41. Piazza P.V., Deminiere J.M., le Moal M., and Simon H. Stress- and pharmacologically-induced behavioral sensitization increases vulnerability to acquisition of amphetamine self-administration. Brain Res. 514 (1990) 22-26
42. Raffa R.B., Kim A., Rice K.C., de Costa B.R., Codd E.E., and Rothman R.B. Low affinity of FMRFamide and four FaRPs (FMRFamide-related peptides), including the mammalian-derived FaRPs F-8- amide (NPFF) and A-18-Famide, for opioid mu, delta, kappa 1, kappa 2a, or kappa 2b receptors. Peptides 15 (1994) 401-404
43. Robinson T.E., and Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. Rev. 396 (1986) 157-198
44. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18 (1993) 247-291
45. Rothman R.B. review of the role of anti-opioid peptides in morphine tolerance and dependence. Synapse 12 (1992) 129-138
46. Rothman R.B., Brady L.S., Xu H., and Long J.B. Chronic intraventricular infusion of the anti-opiod peptide, Phe-Leu-Phe-Gln-Pro-Gln-Arg-Phe-NH2 (NPFF), downregulates mu opioid binding sites in rat brain. Peptides 14 (1993) 1271-1277
47. Roumy M., and Zajac J.M. Neuropeptide FF, pain and analgesia. Eur. J. Pharmacol. 345 (1998) 1-11
48. Segal D.S., and Kuczenski R. Repeated cocaine administration induces behavioral sensitization and corresponding decreased extracellular dopamine responses in caudate and accumbens. Brain Res. 577 (1992) 351-355
49. Segal D.S., and Mandell A.J. Long-term administration of d-amphetamine: progressive augmentation of motor activity and stereotypy. Pharmacol. Biochem. Behav. 2 (1974) 249-255
50. Shippenberg T.S., Heidbreder C., and Lefevour A. Sensitization to the conditioned rewarding effects of morphine: pharmacology and temporal characteristics. Eur. J. Pharmacol. 299 (1996) 33-39
51. Simonin F., Schmitt M., Laulin J.P., Laboureyras E., Jhamandas J.H., MacTavish D., Matifas A., Mollereau C., Laurent P., Parmentier M., Kieffer B.L., Bourguignon J.J., and Simonnet G. RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc. Natl. Acad. Sci. USA 103 (2006) 466-471
52. Spanagel R., and Shippenberg T.S. Modulation of morphine-induced sensitization by endogenous kappa opioid systems in the rat. Neurosci. Lett. 153 (1993) 232-236
53. Stewart J., and Badiani A. Tolerance and sensitization to the behavioral effects of drugs. Behav. Pharmacol. 4 (1993) 289-312
54. Stinus L., Allard M., Gold L., and Simonnet G. in CNS neuropeptide FF-like material, pain sensitivity, and opiate dependence following chronic morphine treatment. Peptides 16 (1995) 1235-1241
55. Tang J., Yang H.Y., and Costa E. Inhibition of spontaneous and opiate mediated nociception by an andogenous neuropeptide with Phe-Met-Arg-Phe-NH2-like immunoreactivity. Proc. Natl. Acad. Sci. USA 81 (1984) 5002-5005
56. Vezina P., Kalivas P.W., and Stewart J. Sensitization occurs to the locomotor effects of morphine and the specific mu opioid receptor agonist, DAGO, administered repeatedly to the ventral tegmental area but not to the nucleus accumbens. Brain Res. 417 (1987) 51-58
57. Walaas I. Biochemical evidence for overlapping neocortical and allocortical glutamate projections to the nucleus accumbens and rostral caudatoputamen in the rat brain. Neuroscience 6 (1981) 399-405
58. Wise R.A., and Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94 (1987) 469-492
59. Wolf M.E., and Jeziorski M. Coadministration of MK-801 with amphetamine, cocaine or morphine prevents rather than transiently masks the development of behavioral sensitization. Brain Res. 613 (1993) 291-294
60. Wolf M.E., Dahlin S.L., Hu X.T., Xue C.J., and White K. Effects of lesions of prefrontal cortex, amygdala, or fornix on behavioral sensitization to amphetamine: comparison with N-methyl-d-aspartate antagonists. Neuroscience 69 (1995) 417-439
61. Yang H.Y., and Martin R.M. Isolation and characterization of a neuropeptide FF-like peptide from brain and spinal cord of rat. Soc. Neurosci. Abstr. 21 (1995) 760
62. Yang H.Y., Fratta W., Majane E.A., and Costa E. Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine. Proc. Natl. Acad. Sci. USA 82 (1985) 7757-7761